GLPs & 503Bs in 2026: What Pharmacies, Clinics & Prescribers Must Know | Legal & Compliance Update скачать в хорошем качестве

GLPs & 503Bs in 2026: What Pharmacies, Clinics & Prescribers Must Know | Legal & Compliance Update

As GLP therapies continue to evolve and regulatory scrutiny increases, pharmacies, clinics, and prescribers are facing a rapidly changing landscape heading into 2026. In this educational webinar, Dr. Nicolette Mathey (Founder of Atrium24) is joined by healthcare attorney Dae Lee for a deep dive into the current legal, regulatory, and compliance realities surrounding GLPs, 503A compounding, and 503B outsourcing facilities. This conversation is designed to help healthcare stakeholders understand what’s changing, what’s compliant, and what to be watching right now — without hype or sales pitches. What You’ll Learn in This Webinar • The current state of GLPs heading into 2026 • Why independent pharmacies may see opportunity in the next few years • The difference between 503A and 503B in the GLP supply chain • What the FDA is (and is not) enforcing today • The Strive v. Lilly & Novo Nordisk lawsuit and why it matters • How Big Pharma pressure is impacting prescribers, telemedicine, and compounding • State-level legislative activity targeting compounding pharmacies • FTC vs FDA enforcement considerations • Why compliant access and transparency matter now more than ever This session is educational and compliance-focused and is intended for: • Independent pharmacy owners • Clinics dispensing or prescribing GLPs • Prescribers navigating compounded therapies • Healthcare professionals evaluating compliant care models ⏱️ Timestamps 00:00 – Introduction & webinar overview 01:30 – What 2026 could mean for independent pharmacies 03:00 – PBM pressure, reimbursement trends & direct-to-consumer models 06:30 – Why compounding continues to matter for patient care 08:45 – GLPs, compounding, and FDA enforcement realities 09:20 – Overview of the Strive v. Lilly & Novo Nordisk lawsuit 12:40 – Allegations of patient and prescriber steering 15:40 – Market share, antitrust concerns & FTC considerations 18:20 – Pharma pressure on platforms, payment processors & social media 22:00 – State legislation targeting compounding pharmacies 26:45 – Defining compounding: 503A vs 503B 29:00 – Scale, patient-specific prescriptions & legal gray areas 33:00 – Vertical integration parallels with PBMs 37:00 – FDA inspections & what they mean (and don’t mean) 39:00 – FTC enforcement outlook vs FDA action 42:30 – AtriumX conference & next steps 44:00 – Atrium24 GPO & compliant access models 46:30 – Final thoughts: adapting to survive and thrive 🔗 Learn More & Contact Information Atrium24 Website: https://atrium24.io Learn more about Atrium24’s consulting, Dotti platform, and GPO initiatives designed to support compliant growth for independent pharmacies. Dae Lee, Healthcare Attorney Firm: Buchanan Ingersoll & Rooney LinkedIn:   / dae-y-lee   For legal questions regarding compounding, GLPs, and regulatory compliance, consult qualified legal counsel. Disclaimer This webinar is for educational purposes only and does not constitute legal advice. Always consult legal counsel regarding compliance and regulatory matters specific to your business.